Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

dual tasking

- PMLiVE

Germany backs use of AZ/Oxford COVID-19 vaccine in over-65s

Country's Health Ministry also recommended extending gap between doses to 12 weeks

- PMLiVE

GSK, Vir halt enrolment of phase 3 COVID-19 antibody study

Move comes after recommendation from independent data and safety monitoring board

- PMLiVE

Amgen adds to oncology pipeline with $1.9bn Five Prime Therapeutics acquisition

Five Prime's pipeline includes potentially first-in-class anti-FGFR2b antibody bemarituzumab

Gene Editing and Precision Medicine: The Future of Healthcare?

Dr. Oscar Segurado, Chief Medical Officer at ASC Therapeutics, dives into advanced gene therapies, gene editing, and personalized medicine. We also explore the many different hats he wears as CMO, consultant,...

Impetus Digital

CRM Design and Optimization for Life Science Organizations

John Leombruno, CEO of OkRx, shares how his company is working to improve PSP strategy and operations in Canada. He also discusses the impact of COVID-19 on PSPs, digital transformation, clinical...

Impetus Digital

- PMLiVE

CureVac signs manufacturing agreement with Novartis for COVID-19 vaccine candidate

Novartis will aid manufacturing for up to 50 million doses of CureVac's vaccine in 2021

- PMLiVE

Pfizer’s ALK inhibitor Lorbrena scores expanded FDA approval for first-line NSCLC

The European Medicines Agency is also reviewing an application for the drug

- PMLiVE

MHRA to fast-track vaccines modified for new COVID-19 variants

Pfizer, Moderna and AstraZeneca are all working on modified vaccines

- PMLiVE

EMA begins rolling review process for Sputnik V COVID-19 vaccine

Late-stage trial results found vaccine gives 91.6% protection against COVID-19

- PMLiVE

Syneos Health Communications announces senior hires to Europe-based team

New hires bolster market access, scientific and medical and creative capabilities

- PMLiVE

Novavax seeks FDA emergency approval for COVID-19 vaccine by May

Company is hoping FDA will review data from a UK-based trial

- PMLiVE

AbbVie buys exclusive right to acquire Mitokinin’s Parkinson’s asset

Company can acquire asset following the completion of IND enabling studies

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links